Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis

Digestive Diseases and Sciences

Volumn 52, Issue 12, 2007, Pages 3465-3472

  Tahan, Veysel ^a,d   Eren, Fatih ^b   Avsar, Erol ^b   Yavuz, Dilek ^a   Yuksel, Meral ^a   Emekli, Ebru ^b   Imeryuz, Nese ^a   Celikel, Cigdem ^a   Uzun, Hafize ^c   Haklar, Goncagul ^a   Tozun, Nurdan ^a,b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Cytokine; Insulin resistance; Interleukin; Nonalcoholic fatty liver disease; Oral glucose tolerance test; Reactive oxygen species; Rosiglitazone; Tumor necrosis factor

Indexed keywords

CYTOKINE; FREE RADICAL; INTERLEUKIN 1BETA; INTERLEUKIN 6; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DIET; DRUG EFFECT; HEPATITIS; INSULIN RESISTANCE; MALE; METHIONINE AND CHOLINE DEFECIENT DIET; NONALCOHOLIC FATTY LIVER; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; CHEMILUMINESCENT MEASUREMENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; INSULIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35948957796     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9756-x     Document Type: Article

References (30)

1. Linden D, William-Olsson L, Ahnmark A, Ekroos K, Hallberg C, Sjogren HP, Becker B, Svensson L, Clapham JC, Oscarsson J, Schreyer S (2006) Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 20:434-443
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894
3. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519-525
4. Neuschwander-Tetri BA, Isley WL, Oki JC et al (1998) Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 129:38-41
5. Kohlroser J, Mathai J, Reicheld J, Banner BF, Bonkovsky HL (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272-276
6. Wagstaff AJ, Goa KL (2002) Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837
7. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR (2003) Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38:434-440
8. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017
9. Davies GR, Simmonds NJ, Stevens TR, Seaff MT, Banatvala N, Laurenson IF, Blake DR, Rampton DS (1994) Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 35:179-185
10. Haklar G, SayIn-Özveri E, Yüksel M, Aktan AÖ, YalçIn AS (2001) Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 165:219-224
11. Yagi K (1984) Assay for blood plasma or serum. Methods Enzymol 105:328-331
12. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y (2003) Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 26:2426-2432
13. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic seatohepatitis: a proposal for the grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474
14. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778
15. Pamuk GE, Sonsuz A (2003) N-Acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 18:1220-1221
16. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998-1003
17. Hockings PD, Changani KK, Saeed N, Reid DG, Birmingham J, O'Brien P, Osborne J, Toseland CN, Buckingham RE (2003) Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes Metab 5:234-243
18. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ (2003) Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 52:1078-1083
19. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845
20. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192
21. Baroni GS, Pastorelli A, Manzin A, Benedetti A, Marucci L, Solforosi L, Di Sario A, Brunelli E, Orlandi F, Clementi M, Macarri G (1999) Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 19:212-219
22. Cortez-Pinto H, Baptista A, Camilo ME, de Moura MC (2001) Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterology 48:87-90
23. Tahan V, Eren F, Yavuz D et al (2003) Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. J Hepatol 38(Suppl 2):202
24. Tahan V, Avsar E, Eren F, Yavuz D, Emekli E, Yuksel M, Goren Z, Imeryuz N, Celikel C, Haklar G, Tozun N (2004) The effect of rosiglitazone on methionine and choline deficient diet model of non-alcoholic steatohepatitis in rats. J Hepatol 40(Suppl 1):172
25. Tahan V, Yavuz D, Imeryuz N, Avsar E, Tozun N (2004) Oral glucose tolerance deteriorates in rats fed with methionine choline deficient diet. J Hepatol 41:352
26. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
27. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
28. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735
29. Asada K, Sasaki S, Suda T, Chida K, Nakamura H (2004) Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 169:195-200
30. Rinella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40:47-51